Clinical Trials Logo

Neurogenic Detrusor Overactivity clinical trials

View clinical trials related to Neurogenic Detrusor Overactivity.

Filter by:

NCT ID: NCT01539707 Completed - Overactive Bladder Clinical Trials

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Start date: March 13, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after taking a single oral dose. If the bladder contracts strongly and without warning, the muscles surrounding the urethra (detrusor muscles) may not be able to keep urine from passing. This may happen as a consequence of spinal cord defects, and then is called neurogenic detrusor overactivity.

NCT ID: NCT01091727 Completed - Clinical trials for Neurogenic Detrusor Overactivity

Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity

Start date: October 2006
Phase: Phase 3
Study type: Interventional

This is a prospective, multicentre (7 sites), randomized, double-blind, study comparing intravesical injection of BOTOX to placebo in 56 subjects with NDO secondary to spinal cord injury or multiple sclerosis. Study subjects will be randomized to one of the following two treatment groups: Group 1 n=28 BOTOX - 300U Group 2 n=28 Placebo BOTOX (saline) All study subjects will receive one injection cycle (BOTOX 300U or Placebo) at Visit 2 (Treatment, Day 0) as per Supplement III. The study duration is approximately 61 weeks and consists of a Pre-Treatment Evaluation, a Treatment/Randomization Visit (Visit 2, Day 0), Telephone Follow-ups at 1, 3 and 4 weeks post-treatment, and Follow-up Visits at 6, 24 and 36 weeks (Visits 3 to 5). At Week 36, subjects will be offered open-label BOTOX 300U and will be followed for an additional 6 months, returning for evaluations at Weeks 48 and 60.

NCT ID: NCT00857896 Completed - Overactive Bladder Clinical Trials

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.

NCT ID: NCT00800462 Completed - Spinal Cord Injury Clinical Trials

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

Start date: March 2008
Phase: Phase 4
Study type: Interventional

This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.